Power3 Medical Continues Validation of NuroPro As Diagnostic Tool

Aug 6, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Power3 Medical
Products, Inc. (PWRM) said it is continuing the validation of the NuroPro(TM) as a
diagnostic tool in the early stage assessment of the diagnosis and progression of
ALS, Alzheimer's, Parkinson's, and other neurodegenerative diseases.

In support of the exclusive worldwide license agreement recently signed between
Baylor College of Medicine and Power3 Medical, Dr. Stan Appel has agreed to
provide additional patient samples to continue the ongoing validation program. This
proteomic analysis of patient samples utilizing the NuroPro is supplemental to
current assessments performed by Dr. Appel in patients' diagnosis. As of today, 219
samples have been analyzed with results above expectations.

According to Dr. Ira Goldknopf, "The ongoing clinical validation of the NuroPro has
shown great promise as a tool for assessment of neurodegenerative disease. The
NuroPro, being used in comparison with current assessment by Dr. Appel as a
diagnostic tool, demonstrates its accuracy and potential for use in early diagnosis. It
is rewarding to see our proprietary technology being evaluated concurrently with the
diagnosis of patients."

Power 3 Medical Products is enrolled in Investrend Research's unique and
pioneering professional analyst program, which facilitates independent analysts to
provide financial coverage for shareholders and investors in companies that
otherwise would have little or no analyst following.

Investrend Research analyst Ryan Fuhrmann, CFA, is preparing a Criterion
Research report.

The Investrend Research program is the largest in the world and includes a number
of safeguards to reduce or eliminate conflict. These systems, including media
coverage and endorsements, may be accessed at
http://www.investrendresearch.com

Investrend Research subscribes to the "Standards for Independent Research
Providers" at http://www.firstresearchconsortium.com, and adheres to the
Guidelines for independent providers jointly endorsed by the National Investor
Relations Institute (http://www.niri.org) and the Association for Investment
Management and Research (http://www.aimr.org).

The Dow Jones Newswires has stated that independent research has been growing
in credibility over the past 18 months, specifically citing Investrend Research, and
the New York Times has reported a survey by Charles Schwab & Co. reveals an
astonishing 78 percent of active stockholders now "value research from
independent firms over analysis by Wall Street firms with financial ties to the
companies they are rating." A survey at Investopedia reveals that 74.7% of
investors say that "legitimate fee-based research is objective and useful," and
70.9% say that a company that enrolls for "legitimate fee-based research is making
a positive statement about its investment potential."

Enrollment fees for Criterion coverage are $8,940, and the fees were paid by Focus
Partners, LLC. There are never any fees associated with FinancialWire, which
independently covers a wide range of corporate news, including but not limited to
those that are or have been enrolled in Investrend's platforms.

Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press release
service and receives no compensation for its news or opinions. Other divisions of
Investrend, however, provide shareholder empowerment platforms such as forums,
independent research and webcasting. For more information or to receive the
FirstAlert daily summary of news, commentary, research reports, webcasts, events
and conference calls, click on http://www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268

FinancialWire
http://www.financialwire.net

For more information on Parkinson's and other movement disorders,
go to Worldwide Education and Awareness for Movement Disorders at
http://www.wemove.org

For additional information about dystonia, go to
http://www.spasmodictorticollis.org

SOURCE: Investor's Business Daily
http://www.investors.com/breakingnews.asp?journalid=22542131&brk=1

* * *

Related References:

The Breast Cancer NAFTest is Power3 Medical's initial breast cancer product
developed in collaboration with the University of Texas MD Anderson Cancer
Center. The test utilizes fluids from the breast called nipple aspirates to identify
groups of breast cancer proteins. The collection of the nipple aspirate fluid is a non-
invasive procedure utilizing a modified breast pump to obtain a drop of fluid from the
nipple. The aspirate is analyzed to identify the specific breast cancer protein
footprints. Power3 believes this test is the first test of its type that detects breast
cancer earlier than any technologies currently allow. The initial proof-of-concept has
been completed with remarkable effectiveness and sensitivity. Clinical trial
preparation is currently underway.
http://www.power3medical.com/products/naftest.aspx?level=0:

The NuroPro Blood Test is Power3’s diagnostic tool for the early detection of
Neurodegenerative diseases. The analysis is designed as a tool for physicians to
diagnose various degenerative diseases of the brain and nervous system. The test
involves monitoring the concentration of 9 proteins in blood serum to accurately
detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease),
and Parkinson’s disease . Early detection of these diseases will allow physicians to
intervene at an early stage to delay disease progression, potentially allowing
patients to outlive their debilitating symptoms.

The NuroPro Test is currently in the development stages. The company has
completed proof-of-concept and first stage of clinical validation studies, with results
exceeding expectations. The validation is done in collaboration with Dr. Stan Appel,
Chairman of the Department of Neurology at Baylor College of Medicine.
http://www.power3medical.com/products/nuroprotest.aspx?level=1

How It Works
Neurodegenerative disease, such as Alzheimer’s, ALS, and Parkinson’s disease
attack the Nervous system, causing healthy cells to deteriorate and die. When a cell
dies, certain proteins are released into the blood stream. Power3’s NuroPro Test
monitors the concentration of these proteins to determine which neurodegenerative
disease, if any, is afflicting the patient.
http://www.power3medical.com/products/ndwork.aspx?level=10

Parkinson’s disease is a progressive and degenerative neurological disorder
involving the loss of nervous tissue in the brain. When these motor neurons die or
become impaired, the patient becomes unable to direct or control movement in a
normal manner.

Behavior is typically characterized by the following motor symptoms:

Rigidity: stiffness or inflexibility of the limbs and joints
Bradykinesia/akinesia: slowness of movement/absence of movement
Tremor: involuntary, regular, rhythmic shaking of a limb, the head, the mouth, the
tongue, or the entire body
Postural instability: impaired balance and coordination

A variety of medications provide relief from the symptoms, but no drug can stop the
progression of the disease. In some cases, surgery is an appropriate treatment.
Physical therapy and muscle strengthening exercised are also recommended by
physicians.

http://www.power3medical.com/products/parki.aspx?level=122

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn